My Treatment Approach: Translating Evidence to Clinical Practice in Advanced RCC   - Episode 3

Ongoing Clinical Trials in the front-line setting of advanced non-clear cell RCC

,

Moshe Ornstein, MD, presents an overview of the current front-line treatment options for advanced non-clear cell renal cell carcinoma, focusing on the PAPMET regimen and the promising results from the Phase 2 study investigating the combination of nivolumab and cabozantinib.

EP. 1: Evolving Treatment Standards in Non-Clear Cell RCC
EP. 2: Extended Follow Up of KEYNOTE-B61
Now Viewing
EP. 3: Ongoing Clinical Trials in the front-line setting of advanced non-clear cell RCC
EP. 4: STELLAR 304: Zanzalintinib plus nivolumab in non-clear cell RCC
EP. 5: Case Presentation: 61-year-old male Renal Cell Carcinoma
EP. 6: Use of Combination Regimens in Frontline RCC
EP. 7: Treatment Decision Making in first-line combinations for advanced RCC
EP. 8: AE Management for Combination Regimens in Advanced RCC
EP. 9: AE Management for Combination Regimens in Advanced RCC
EP. 10: Optimizing Treatment in Advanced RCC
EP. 11: Dr Albiges Discusses a Non-Clear Cell RCC Patient Profile
EP. 12: Updates in the Treatment Approach for Non-clear cell RCC
EP. 13: Dr Albiges Reviews Long term follow up data from KEYNOTE-B61
EP. 14: Emerging Therapies in the Front-line Setting of Advanced non-clear cell RCC
EP. 15: Biomarker-driven combination treatment approach in non-clear cell RCC (Met-driven)
EP. 16: Summary and Forward Looking for RCC
  1. Please review some of the other therapies for the treatment of advanced non-clear cell RCC in the front-line setting:
    1. PAPMET (Tripathi A et al. JCO 2023)
    2. Phase 2 study (Nivo + Cabo): (Lee CH, et al. ASCO 2023. Abstract 4537)